Tobramycin: A Review of its Antibacterial and Pharmacokinetic Properties and Therapeutic Use

  title={Tobramycin: A Review of its Antibacterial and Pharmacokinetic Properties and Therapeutic Use},
  author={Rex N. Brogden and Roger Martin Pinder and Phyllis R. Sawyer and Trevor M. Speight and Graeme S. Avery},
SummarySynopsis: Tobramycin is a new aminoglycoside antibiotic with a broad antibacterial spectrum in vitro, and pharmacokinetic properties similar to those for gentamicin. Tobramycin is more active than gentamicin against Pseudomonas aeruginosa and active against many gentamicin resistant strains, but is not active against enterobacteriaceae resistant to gentamicin.Theoretically, tobramycin has an advantage over gentamicin against infections caused by P. aeruginosa, but any advantage in… 
Aminoglycosides: An Overview.
Aminoglycosides found widespread use as first-line agents in the early days of antimicrobial chemotherapy, but were eventually replaced in the 1980s with cephalosporins, carbapenems, and fluoroquinolones.
Tobramycin for the treatment of bacterial pneumonia in children
Systematic reviews suggest that tobramycin inhalation improves outcome, decreases theneed for hospitalization and decreases the need for use of frequent systemic antibiotics in CF patients colonized with pseudomonas.
In Vivo and In Vitro Efficacy of Minocycline-Based Combination Therapy for Minocycline-Resistant Acinetobacter baumannii
The clinical use of minocycline in combination with colistin for the treatment of mincycline-resistant A. baumannii may warrant further investigation, and only the combination with Colistin produced a fractional inhibitory concentration index comparable to that achieved with meropenem combined with colistsin.
Antivirulence Properties of a Low-Molecular-Weight Quaternized Chitosan Derivative against Pseudomonas aeruginosa
An antivirulence activity of QAL is demonstrated, possibly due to polymer intracellular localization and QS-inhibition, and its ability to inhibit P. aeruginosa growth synergizing with tobramycin is demonstrated.
Minocycline: far beyond an antibiotic
A review will cover the most important topics in the pharmacology of minocycline to date, supporting its evaluation as a new therapeutic approach for many of the diseases described herein.
Antibacterial Drugs Today
The sulphonamides, the natural and semi-synthetic penicillins, cotrimoxazole, chloramphenicol, tetracyclines, the macrolides, lincomycin and clindamycin, fusidic acid, and the urinary antiseptics are discussed.
The bactericidal activity of ampicillin, amoxicillin, tetracycline, and doxycycline against H. influenzae under various conditions of culture.
  • K. Bartmann, R. Tarbuc
  • Biology, Medicine
    Zentralblatt fur Bakteriologie, Mikrobiologie, und Hygiene. Series A, Medical microbiology, infectious diseases, virology, parasitology
  • 1985
Combining hydroxychloroquine and minocycline: potential role in moderate to severe COVID-19 infection
Additive antimicrobial and anticytokine effects of both drugs may reduce the morbidity and mortality among patients with COVID-19 and may act as a cheaper alternative to the costlier drugs, however, thorough clinical research is warranted.
A comparative study of amoxycillin and pivampicillin in persistent Haemophilus influenzae infection of the lower respiratory tract in children with chronic lung disease.
The high number of treatment failures and the development of resistant strains indicate that betalactamase inhibitors may possibly improve the efficacy of these drugs, especially of amoxycillin, in these patients.


Comparative Activity of Tobramycin, Amikacin, and Gentamicin Alone and with Carbenicillin Against Pseudomonas aeruginosa
The effect of gentamicin against 130 clinical isolates of Pseudomonas aeruginosa was compared with that of two investigational aminoglycoside antibiotics, tobramycin and amikacin, and the combination of carbenicillin and amkacin enhanced inhibition against all but two of the isolates.
Antimicrobial activity of tobramycin and gentamicin used in combination with cephalothin and carbenicillin
Some antibacterial advantage of tobramycin over gentamicin has been observed for 17 of 32 strains of Pseudomonas aeruginosa in which minimum inhibitory concentrations for tobramYcin and Gentamicin were higher than 1.5 µg/ml, however, cross-resistance between these antibiotics has be observed for several strains.
Newer Aminoglycosides—Amikacin and Tobramycin: An in-vitro Comparison with Kanamycin and Gentamicin
Amikacin was the most active compound against a selection of strains chosen because of their resistance to one or more of the aminoglycosides and seems to be superior to gentamicin in terms of its in-vitro properties.
Antibacterial activity of tobramycin against gram-negative bacteria and the combination of ampicillin/tobramycin against E. coli.
In vitro rationale for the consideration of tobramycin for clinical use in patients with Psuedomonas infections for the combination of ampicillin and tobramYcin for the treatment of selected E.coli infections is provided.
Comparative Clinical Study of Tobramycin and Gentamicin
The clinical results were much better in urinary tract infections than in wound infections, pulmonary infections, septicemia, and meningitis, and the frequency of adverse reactions encountered in the present series was similar for both drugs.
Comparison of Five Aminocyclitol Antibiotics In Vitro Against Enterobacteriaceae and Pseudomonas
The in vitro susceptibility of 163 strains of Enterobacteriaceae and 23 isolates of Pseudomonas aeruginosa to various concentrations of gentamicin, kanamycin, spectinomycin, tobramycin, and BB-K8, a
Tobramycin: bacteriological evaluation
Of particular interest are the susceptibilities of strains of Pseudomonas aeruginosa to lower concentrations of tobramycin than to gentamicin, and the susceptibility of some “gentamicin-resistant‘’ strains of P. aerug inosa to tobramYcin.
In Vitro Evaluation of Tobramycin, a New Aminoglycoside Antibiotic
One hundred fifty-two strains of Escherichia coli, Klebsiella-Enterobacter, Pseudomonas aeruginosa, Proteus species, and Staphylococcus aureus were inhibited by 3.1 μg of tobramycin/ml in a
In Vitro Studies of Tobramycin, an Aminoglycoside Antibiotic
Tobramycin is an aminoglycoside antibiotic which has excellent antibacterial activity against Pseudomonas, Staphylococcus aureus, and many members of the Enterobacteriaceae. Most strains of Serratia,